VHL and hepatocellular carcinoma: The von Hippel–Lindau (VHL) protein targets HIF-1/2α subunits for degradation and participates in modulating the activities of HIFs and NF-κB. Recently, it was shown that pVHL overexpression synergizes with doxorubicin in the treatment of HCC [61].